Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth (Q44120544)

3

1 reference

30 November 2017

Gail D Lewis

4

1 reference

30 November 2017

Brian Higgins

5

1 reference

30 November 2017

Paul I Pisacane

6

1 reference

30 November 2017

Julie A Lofgren

7

1 reference

30 November 2017

Charles Tindell

8

1 reference

30 November 2017

Douglas P Evans

9

1 reference

30 November 2017

Krista Maiese

10

1 reference

30 November 2017

Howard I Scher

11

1 reference

30 November 2017

Mark X Sliwkowski

Amphiregulin is coordinately expressed with heparin-binding epidermal growth factor-like growth factor in the interstitial smooth muscle of the human prostate

12

1 reference

30 November 2017

1 August 2002

1 reference

30 November 2017

1 reference

30 November 2017

2

1 reference

30 November 2017

127-137

1 reference

30 November 2017

2

1 reference

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

ZD1839 ('Iressa') as an anticancer agent

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Inhibitors of tyrosine kinases in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Heparin-binding epidermal growth factor-like growth factor is an autocrine mediator of human prostate stromal cell growth in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

A novel method for real time quantitative RT-PCR.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Androgen receptor signaling in androgen-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Real time quantitative PCR

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Binding interaction of the heregulinbeta egf domain with ErbB3 and ErbB4 receptors assessed by alanine scanning mutagenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Binding specificities and affinities of egf domains for ErbB receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

The EGF receptor family as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Her-2/neu oncogene amplification in clinically localised prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

HER2 protein expression and gene amplification in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Analysis of heregulin-induced ErbB2 phosphorylation with a high-throughput Kinase receptor activation enzyme-linked immunosorbant assay

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Smart drugs: tyrosine kinase inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Her-2-neu expression and progression toward androgen independence in human prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

1 reference

7 January 2021

The epidermal growth factor receptor and its inhibition in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021

From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900097-1

7 January 2021